Applied Therapeutics, a Phase 2 biotech developing therapies for diabetic cardiomyopathy, filed on Friday with the SEC to raise up to $86 million in an initial public offering.
The New York, NY-based company was founded in 2016 and plans to list on the Nasdaq under the symbol APLT. Citi, Cowen and UBS Investment Bank are the joint bookrunners on the deal. No pricing terms were disclosed.
